Showing results (1-10 of 230) with videos related to

Sort By:
Pageof 23
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|October 31, 2017
Multiple sclerosis and agingCéline Louapre, Caroline Papeix, Catherine Lubetzki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 25, 2013
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?Elisabeth Maillart, Céline Louapre, Catherine Lubetzki, et al.
Multiple Sclerosis and Related Disorders|February 13, 2018
Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?Elisabeth Maillart, Anaïs Lippi, Catherine Lubetzki, et al.
Multiple Sclerosis and Related Disorders|September 11, 2020
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?Elisabeth Maillart, Caroline Papeix, Catherine Lubetzki, et al.
Multiple Sclerosis and Related Disorders|March 23, 2024
Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapiesOussama Sahloul, Céline Louapre, Ysoline Beigneux, et al.
Multiple Sclerosis and Related Disorders|June 17, 2017
Fatigue evaluation in fingolimod treated patients: An observational studyMarion Masingue, Rabab Debs, Elisabeth Maillart, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2023
Recurrence of severe symptomatic late-onset neutropenia on ocrelizumabYsoline Beigneux, Celine Louapre, Kevin Bihan, et al.
Frontiers in Neurology|May 23, 2017
Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French CenterThomas Roux, Elisabeth Maillart, Jean-Sébastien Vidal, et al.
Neurology|February 26, 2017
Fast multiple sclerosis progression in North Africans: Both genetics and environment matterYoussef Sidhom, Elisabeth Maillart, Sophie Tezenas du Montcel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2017
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?Marine Boudot de la Motte, Céline Louapre, Anne Bertrand, et al.
Pageof 23